SCHEMBL3203900

SCHEMBL3203900

C/C(=C/C(=O)O)c1ccc(C)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
NR4A1 P22736 1/20 0.51
NR4A2 P43354 1/20 0.51
NR4A3 Q92570 1/20 0.51
TBXAS1 P24557 3/20 0.44
MTOR P42345 1/20 0.43
KCNQ3 O43525 2/20 0.41
KCNQ2 O43526 2/20 0.41
KCNE1 P15382 2/20 0.41
KCNQ1 P51787 2/20 0.41
KCNQ5 Q9NR82 1/20 0.41
F2 P00734 1/20 0.40
PLG P00747 1/20 0.40
PRSS1 P07477 1/20 0.40
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572494 1.00 HDAC1 (0.53) HDAC1HDAC6NR4A1NR4A2NR4A3
SCHEMBL2576657 0.86 NR4A1 (0.54) NR4A1NR4A2NR4A3TBXAS1KCNQ3
SCHEMBL2576659 0.86 NR4A1 (0.54) NR4A1NR4A2NR4A3TBXAS1KCNQ3
SCHEMBL111301 0.84 CES2 (0.52) NR4A1NR4A2NR4A3TBXAS1F2
Hydrochloric Acid SCHEMBL6786928 0.82 TBXAS1 (0.52) NR4A1NR4A2NR4A3TBXAS1F2
SCHEMBL22397208 0.81 NR4A1 (0.50) NR4A1NR4A2NR4A3TBXAS1KCNQ3
SCHEMBL22397207 0.81 NR4A1 (0.50) NR4A1NR4A2NR4A3TBXAS1KCNQ3
Hydrochloric Acid SCHEMBL3024028 0.80 HDAC1 (0.50) HDAC1HDAC6NR4A1NR4A2NR4A3
Hydrochloric Acid SCHEMBL3024030 0.80 HDAC1 (0.50) HDAC1HDAC6NR4A1NR4A2NR4A3
SCHEMBL4023529 0.79 NR4A1 (0.59) NR4A1NR4A2NR4A3TBXAS1KCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710077-B2 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2102164-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI AVENTIS (FR) 2010-12-01 EP disclosed
US-20100056553-A1 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-03-04 US disclosed
EP-2102164-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-09-23 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
WO-2008077556-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 HDAC1 1000/4885HDAC6 381/4885NR4A1 3842/4885
US-20100056553-A1 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 HDAC1 1281/4885HDAC6 330/4885NR4A1 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.